Daclatasvir (Daklinza) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C, depending on their level of fibrosis. It is taken with sofosbuvir or peginteron alfa, and sometimes with a drug called ribavirin. See tables 1, 2 and 3.

Table 1 If your hepatitis C has not been treated before

Type of hepatitis C

Treatment recommended by NICE

Length of treatment

1, without cirrhosis

Daclatasvir plus sofosbuvir only for people with significant fibrosis

12 weeks

4

Daclatasvir plus peginterferon alfa and ribavirin only for people with significant fibrosis or cirrhosis

24 weeks

Table 2 If your hepatitis C has been treated before

Type of hepatitis C

Treatment recommended by NICE

Length of treatment

1 or 4 without cirrhosis

Daclatasvir plus sofosbuvir only for people with significant fibrosis

12 weeks

4

Daclatasvir plus peginterferon alfa and ribavirin only for people with significant fibrosis or cirrhosis

24 weeks

 Table 3 If you cannot have interferon

Type of hepatitis C

Treatment recommended by NICE

Length of treatment

1, 3 or 4 without cirrhosis

Daclatasvir plus sofosbuvir only for people with significant fibrosis

12 weeks

1 or 4 with cirrhosis

Daclatasvir plus sofosbuvir, with or without ribavirin

24 weeks

3, with cirrhosis

Daclatasvir plus sofosbuvir and ribavirin

24 weeks

What does this mean for me?

If you have genotype 1, 3 or 4 chronic hepatitis C that fits the criteria in tables 1, 2 or 3, and your healthcare team think that daclatasvir is the right treatment, you should be able to have the treatment on the NHS.

The treatment should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking daclatasvir until you and your healthcare team decide it is the right time to stop.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

  • National Institute for Health and Care Excellence (NICE) accreditation logo